Amatuximab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Amatuximab
- DrugBank Accession Number
- DB12845
- Background
Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Amatuximab
- Chimeric monoclonal antibody to mesothelin
- Immunoglobulin G1, anti-(mesothelin) (human-mouse monoclonal MORAb-009 heavy chain), disulfide with human-mouse monoclonal MORAb-009 .Kappa.-chain, dimer
- External IDs
- MORAb-009
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UMesothelin Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Amatuximab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Amatuximab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Amatuximab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amatuximab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Amatuximab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6HP0354G04
- CAS number
- 931402-35-6
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911395
- Wikipedia
- Amatuximab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Malignant Pleural Mesothelioma (MPM) 1 2 Completed Treatment Pancreatic Cancer 1 2 Terminated Treatment Malignant Pleural Mesothelioma (MPM) 1 1 Completed Basic Science Mesothelioma / Non-Small Cell Lung Cancer (NSCLC) / Ovarian Cancer / Pancreatic Cancer 1 1 Completed Treatment Cancer / Mesothelin Positive 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsMesothelin
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Membrane-anchored forms may play a role in cellular adhesion.Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
- Gene Name
- MSLN
- Uniprot ID
- Q13421
- Uniprot Name
- Mesothelin
- Molecular Weight
- 68984.815 Da
Drug created at October 21, 2016 00:41 / Updated at December 01, 2022 23:18